CLINICAL_TRIALS
trial_result
· 2022-11-03
Clinical Trial Update: Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) [Phase 2]
Summary
Phase 2 trial update evaluating maintenance olaparib in metastatic prostate cancer with partial or stable response after docetaxel.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: COMPLETED